Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Large & Mid Cap Fund median (35 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | UTI Large & Mid Cap Fund |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹97.35 |
| 12 Apr 2015 | ₹141.50 |
| 31 May 2016 | ₹123.15 |
| 19 Jul 2017 | ₹143.85 |
| 07 Sep 2018 | ₹144.87 |
| 27 Oct 2019 | ₹130.12 |
| 15 Dec 2020 | ₹154.36 |
| 03 Feb 2022 | ₹208.86 |
| 25 Mar 2023 | ₹204.35 |
| 12 May 2024 | ₹317.32 |
| 01 Jul 2025 | ₹391.88 |
| 20 Aug 2026 | ₹405.83 |
| Metric | UTI · Direct · IDCW NAV ₹99.75 Very High risk ★★★★☆ | Category median Large & Mid Cap Fund · 35 funds |
|---|---|---|
| +5.43% | +4.31% | |
| +17.50% | +12.18% | |
| +15.95% | +12.13% | |
| +11.83% | +9.85% | |
| +10.82% | +11.44% | |
| +15.74% | — | |
| +11.50% | +13.24% | |
| +10.69% | +12.72% | |
| +10.82% | +11.19% | |
| Risk | ||
| 13.70% | 15.59% | |
| 0.80 | 0.20 | |
| 1.10 | 0.26 | |
| -45.84% | -38.41% | |
| Nifty Midcap 150 | — | |
| +1.79% | -3.79% | |
| 0.80 | 0.85 | |
| 83.4% | 81.7% | |
| 68.4% | 93.5% | |
| 1.08% | 1.06% | |
| ₹6,407Cr | ₹3,576Cr | |
| 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 60% | 40% | |
| V Srivatsa · 9.3y | — | |
| 02 Jan 2013 | — | |
| 69 | — | |
| 32.6% | — | |
| 2.2% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.